LTRN News
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical stage drug programs, today announced that Lantern management will be presenting...
Business Wire
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical stage drug programs, today announced that Lantern management will be presenting...
Business Wire
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in Taiwan to open the next stage (Part 2) of its Phase 2 HARMONIC trial of LP-300. The Taiwan Food and Drug Administration (TFDA) approved...
Business Wire
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern, the Company or we), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced the closing of its previously announced registered direct offering of 3,669,725...
Business Wire
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, will present the growth plan for Open-Medicine AI (OMAI) in a live webinar today at 12:30 PM Eastern. Open Medicine AI is the...
Business Wire
Lantern Pharma Secures USPTO Notice of Allowance for LP284 Treatment Patent in Aggressive BCell Lymphomas
Lantern Pharma Inc. (NASDAQ: LTRN), an AIdriven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application...
Business Wire
Lantern Pharma to Present Open-Medicine AI a Multi-Agentic Platform for End-to-End Therapeutic Development Business Model, Roadmap, and Value Proposition on September 23
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business...
Business Wire
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational...
Business Wire
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR and Open-Medicine AI platforms with multiple clinical stage drug programs, today announced that it will host its second quarter 2026...
Business Wire
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which have received Lantern Pharma Board...
Business Wire